Science Corporation, the brain-computer interface startup helmed by Max Hodak, the former president of Neuralink, is gearing up to conduct what could be a landmark moment in neurotechnology: implanting a pea-sized neural sensor directly onto a human brain during an already-scheduled surgical procedure. The move signals an aggressive push into clinical trials and represents a fundamentally different engineering philosophy than its more famous competitor.
What Happened
The company is preparing to place a 520-electrode sensor on the brain’s surface, with the procedure set to be led by Murat Günel, chair of neurosurgery at Yale University. Unlike invasive electrodes that penetrate brain tissue, Science Corp’s approach leverages a biological interface strategy that the company believes offers advantages in terms of safety and longevity. If timelines hold, human clinical trials could begin as early as 2027, potentially opening a new chapter in how we interact with computing technology through neural implants.
Key Details
Science Corp isn’t limiting itself to a single technology pathway. The startup also has PRIMA, a retinal implant system that has already demonstrated remarkable results in a pilot program, successfully restoring functional vision to 38 patients. This dual-track approach—targeting both brain and eye interfaces—positions the company as a comprehensive neural technology platform rather than a single-application player. The partnership with Yale’s prestigious neurosurgery department lends significant credibility to the initiative and suggests the company has cleared substantial regulatory and scientific hurdles before reaching this phase.
What This Means for You
The timing and trajectory of Science Corp’s efforts matter enormously for the broader BCI landscape. A successful human implant and subsequent trials would validate alternative approaches to neural interfaces beyond the intracortical electrode methods that have dominated recent attention. This competition could accelerate innovation across the entire sector, forcing companies to prove efficacy, safety, and biocompatibility at faster rates. For patients, it means multiple technological pathways are being developed simultaneously—potentially offering options suited to different neurological conditions and individual circumstances.
The convergence of biology-first engineering, world-class surgical leadership, and multiple product lines suggests Science Corp is playing a long game in neural interfaces. As we approach the late 2020s, the real race isn’t just about who implants first—it’s about who builds the most reliable, safest, and most effective brain-computer connections. Science Corp’s moves indicate they’re betting heavily that thoughtful biological integration beats raw electrode count.
